Table of Contents Table of Contents
Previous Page  26 / 42 Next Page
Information
Show Menu
Previous Page 26 / 42 Next Page
Page Background

• Response: 33 – 68%

• PFS: 5.5 – 8.4 m

• OS / 1 year OS: 11.6 – 19.2 m / 50 – 86%

• Grade 3/4 AEs: 25 – 72%

• No Impact of PD-L1 Expression

Rizvi N et al, J Clin Oncol 2016;

Liu S et al, ASCO 2017; abstract

Phase I

Nivolumab + CT,

Atezolizumab + CT